Replimune submits Biologics License Application for RP1 to treat advanced melanoma

Replimune has submitted a Biologics License Application (BLA) for its lead candidate, RP1, aimed at treating advanced melanoma in adults who have previously received anti-PD1 therapy. This marks a significant step in the drug's development. The submission is part of the Accelerated Approval pathway, which could expedite the review process. This development highlights Replimune's progress in the competitive field of melanoma treatments. RP1's potential approval could impact treatment options for patients with advanced melanoma, a group that often faces limited choices after initial therapies.